Coming today: Trump’s most aggressive drug pricing move yet
From the article:
Some policy experts cheered Trump's ideas, although they had questions about how the plan would work — "If companies won't sell to Medicare at the benchmark price, what happens?" mused Rachel Sachs of Washington University in St. Louis — or how impactful it would really be.
Read more here!health law policy pharmaceuticals rachel sachs regulation